JP2023548657A5 - - Google Patents
Info
- Publication number
- JP2023548657A5 JP2023548657A5 JP2023521702A JP2023521702A JP2023548657A5 JP 2023548657 A5 JP2023548657 A5 JP 2023548657A5 JP 2023521702 A JP2023521702 A JP 2023521702A JP 2023521702 A JP2023521702 A JP 2023521702A JP 2023548657 A5 JP2023548657 A5 JP 2023548657A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- ring
- substituted
- independently selected
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063089965P | 2020-10-09 | 2020-10-09 | |
| US63/089,965 | 2020-10-09 | ||
| US202163151468P | 2021-02-19 | 2021-02-19 | |
| US63/151,468 | 2021-02-19 | ||
| PCT/US2021/054191 WO2022076831A2 (en) | 2020-10-09 | 2021-10-08 | Methods for treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023548657A JP2023548657A (ja) | 2023-11-20 |
| JP2023548657A5 true JP2023548657A5 (enExample) | 2024-10-15 |
Family
ID=78516928
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023521702A Pending JP2023548657A (ja) | 2020-10-09 | 2021-10-08 | がんの処置に使用するための、ｅｇｆｒおよび／またはｈｅｒ２のヘテロ環阻害剤 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20240101576A1 (enExample) |
| EP (1) | EP4225445A2 (enExample) |
| JP (1) | JP2023548657A (enExample) |
| KR (1) | KR20230107419A (enExample) |
| AU (1) | AU2021358596A1 (enExample) |
| BR (1) | BR112023006531A2 (enExample) |
| CA (1) | CA3198202A1 (enExample) |
| CL (2) | CL2023001012A1 (enExample) |
| IL (1) | IL301929A (enExample) |
| MX (1) | MX2023004085A (enExample) |
| PH (1) | PH12023500010A1 (enExample) |
| TW (1) | TW202227063A (enExample) |
| WO (1) | WO2022076831A2 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201905721D0 (en) | 2019-04-24 | 2019-06-05 | Univ Dundee | Compounds |
| TW202309022A (zh) | 2021-04-13 | 2023-03-01 | 美商努法倫特公司 | 用於治療具egfr突變之癌症之胺基取代雜環 |
| US20250282795A1 (en) * | 2022-04-20 | 2025-09-11 | Celyn Therapeutics, Inc. | EGFR Inhibitors in cancer treatment |
| EP4637754A2 (en) * | 2022-12-23 | 2025-10-29 | Tay Therapeutics Limited | Selective bet inhibitors and uses thereof |
| CN115819418B (zh) * | 2023-02-14 | 2023-04-28 | 山东绿叶制药有限公司 | Plk1激酶抑制剂及其制备方法和应用 |
| CN121712773A (zh) | 2023-06-08 | 2026-03-20 | 安塔列斯疗法股份有限公司 | 1,5-二氢-4h-吡咯并[3,2-c]吡啶-4-酮用于癌症治疗 |
| WO2024254298A1 (en) * | 2023-06-08 | 2024-12-12 | Scorpion Therapeutics, Inc. | A 1,5-dihydro-4h-pyrrolo[3,2-c] pyridin-4-one for use in the treatment of cancer |
| CN119528906A (zh) * | 2023-08-30 | 2025-02-28 | 中国科学院上海药物研究所 | 氮杂螺环类化合物及其制备方法、药物组合物和应用 |
| EP4534085A1 (en) * | 2023-10-03 | 2025-04-09 | Scorpion Therapeutics, Inc. | Compounds for use in methods of treating cancer |
| WO2025251058A1 (en) * | 2024-05-31 | 2025-12-04 | Celyn Therapeutics, Inc. | Egfr inhibitors in cancer treatment |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6906194B2 (en) | 2003-10-08 | 2005-06-14 | Massachusetts Instititue Of Technology | Fluorescence assay for kinase activity |
| US7964729B2 (en) | 2006-08-28 | 2011-06-21 | Massachusetts Institute Of Technology | Sox-based kinase sensor |
| US8546413B2 (en) * | 2009-06-15 | 2013-10-01 | Nerviano Medical Sciences S.R.L. | Substituted pyrimidinylpyrrolopyridinone derivatives, process for their preparation and their use as kinase inhibitors |
| JP5825932B2 (ja) | 2011-08-26 | 2015-12-02 | キヤノン株式会社 | 撮像装置及びその制御方法、プログラム、及び記録媒体 |
| ES2638144T3 (es) | 2011-12-21 | 2017-10-18 | Bayer Intellectual Property Gmbh | Bencilpirazoles sustituidos |
| ES2620316T3 (es) | 2012-05-11 | 2017-06-28 | Bayer Pharma Aktiengesellschaft | Cicloalquenopirazoles sustituidos como inhibidores de BUB1 para el tratamiento del cáncer |
| WO2014147204A1 (en) | 2013-03-21 | 2014-09-25 | Bayer Pharma Aktiengesellschaft | Heteroaryl substituted indazoles |
| HK1218750A1 (zh) | 2013-03-21 | 2017-03-10 | Bayer Pharma Aktiengesellschaft | 3-杂芳基取代的吲唑 |
| HK1223097A1 (zh) | 2013-06-21 | 2017-07-21 | Bayer Pharma Aktiengesellschaft | 杂芳基取代的吡唑 |
| HK1222846A1 (zh) | 2013-06-21 | 2017-07-14 | Bayer Pharma Aktiengesellschaft | 取代的苄基吡唑 |
| ES2652305T3 (es) | 2013-06-21 | 2018-02-01 | Bayer Pharma Aktiengesellschaft | Pirazoles heteroaril sustituidos |
| US9765058B2 (en) | 2013-06-21 | 2017-09-19 | Bayer Pharma Aktiengesellschaft | Substituted benzylpyrazoles |
| CA2928998A1 (en) | 2013-10-30 | 2015-05-07 | Bayer Pharma Aktiengesellschaft | Heteroaryl substituted pyrazoles |
| JP6468611B2 (ja) | 2014-05-13 | 2019-02-13 | アリアド ファーマシューティカルズ， インコーポレイテッド | キナーゼ阻害のためのヘテロアリール化合物 |
| EP3157914B1 (en) | 2014-06-17 | 2018-09-26 | Bayer Pharma Aktiengesellschaft | 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones |
| TN2017000329A1 (en) * | 2015-01-28 | 2019-01-16 | Bayer Pharma AG | 4h-pyrrolo[3,2-c]pyridin-4-one derivatives |
| CN107922389A (zh) | 2015-06-17 | 2018-04-17 | 拜耳制药股份公司 | 3‑氨基‑1,5,6,7‑四氢‑4h‑吲哚‑4‑酮 |
| US10308629B2 (en) | 2015-08-05 | 2019-06-04 | Bayer Pharma Aktiengesellschaft | 1H-pyrrol-3-amines |
| JP6141568B1 (ja) | 2015-09-01 | 2017-06-07 | 大鵬薬品工業株式会社 | 新規なピラゾロ［３，４−ｄ］ピリミジン化合物又はその塩 |
| EP3700904B1 (en) * | 2017-10-24 | 2023-07-19 | Bayer AG | 4h-pyrrolo[3,2-c]pyridin-4-one derivatives |
| EP3755323A4 (en) | 2018-02-23 | 2021-11-24 | The Regents Of The University Of Michigan | EGFR DIMER DISRUPTORS AND THEIR USES |
| CN112236417A (zh) | 2018-06-14 | 2021-01-15 | 达纳-法伯癌症研究所股份有限公司 | 作为her2抑制剂的氰基喹啉酰胺化合物及使用方法 |
| WO2019246541A1 (en) | 2018-06-21 | 2019-12-26 | Dana-Farber Cancer Institute, Inc. | Inhibitors of egfr and methods of use thereof |
| EP3921317B1 (en) * | 2019-02-07 | 2023-08-02 | Bayer Aktiengesellschaft | 3-amino-2-[2-(acylamino)pyridin-4-yl]-1,5,6,7-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one as csnk1 inhibitors |
-
2021
- 2021-10-08 KR KR1020237015734A patent/KR20230107419A/ko active Pending
- 2021-10-08 IL IL301929A patent/IL301929A/en unknown
- 2021-10-08 JP JP2023521702A patent/JP2023548657A/ja active Pending
- 2021-10-08 CA CA3198202A patent/CA3198202A1/en active Pending
- 2021-10-08 PH PH1/2023/500010A patent/PH12023500010A1/en unknown
- 2021-10-08 BR BR112023006531A patent/BR112023006531A2/pt unknown
- 2021-10-08 AU AU2021358596A patent/AU2021358596A1/en active Pending
- 2021-10-08 US US18/030,211 patent/US20240101576A1/en active Pending
- 2021-10-08 WO PCT/US2021/054191 patent/WO2022076831A2/en not_active Ceased
- 2021-10-08 MX MX2023004085A patent/MX2023004085A/es unknown
- 2021-10-08 EP EP21802493.3A patent/EP4225445A2/en active Pending
- 2021-10-08 TW TW110137651A patent/TW202227063A/zh unknown
-
2023
- 2023-04-06 CL CL2023001012A patent/CL2023001012A1/es unknown
-
2025
- 2025-12-22 CL CL2025004052A patent/CL2025004052A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023548657A5 (enExample) | ||
| US20250059218A1 (en) | ENPP1 Inhibitors and Methods of Modulating Immune Response | |
| CN118647620A (zh) | 用于治疗癌症的环状2-氨基-3-氰基噻吩及其衍生物 | |
| CN119841847A (zh) | 用于治疗癌症的环状2-氨基-3-氰基噻吩及其衍生物 | |
| KR102793183B1 (ko) | 헤테로시클릭 rip1 키나제 억제제 | |
| TWI825637B (zh) | 啶－１，６（２ｈ，７ｈ）－二酮 | |
| JP2023543528A5 (enExample) | ||
| JP6664385B2 (ja) | Ｂｕｂ１阻害薬としてのベンジル置換インダゾール類 | |
| AU2016341445B2 (en) | 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinases | |
| JP7491996B2 (ja) | α４β７インテグリンの阻害のための化合物 | |
| JP6530857B2 (ja) | 化合物またはその薬学的に許容される塩もしくは立体異性体、並びにその医薬組成物及び医薬物 | |
| AU2015257456B2 (en) | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer | |
| JP2021523159A (ja) | Ｅｒｂｂ受容体阻害剤 | |
| EP4720072A2 (en) | Ras inhibitors | |
| CA3147266C (en) | Imidazo[4,5-c]pyridine derivatives as toll-like receptor agonsits | |
| PT2791136E (pt) | Triazolpiridinas substituídas e respectiva utilização como inibidores de ttk | |
| JP7706585B2 (ja) | 毛細血管拡張性運動失調症変異（ＡＴＭ）キナーゼの選択的調節物質としての１－イソプロピル－３－メチル－８－（ピリジン－３－イル）－１，３－ジヒドロ－２Ｈ－イミダゾ［４，５－ｃ］シンノリン－２－オンおよびその使用 | |
| CN107849036A (zh) | 二环化合物 | |
| WO2023036156A1 (zh) | Dna-pk选择性抑制剂及其制备方法和用途 | |
| TW201843151A (zh) | 氘化咪唑并[4,5-c]喹啉-2-酮化合物及其於治療癌症之用途 | |
| JP2025503945A (ja) | Ｙａｐ／ｔｅａｄ調節およびそれらの適応症のための化合物および方法 | |
| TW202444385A (zh) | Ｅｇｆｒ降解劑、其藥物組成物及其用途 | |
| US20250376445A1 (en) | Compounds and methods for yap/tead modulation and indications therefor | |
| JP2021526150A (ja) | アデノシン受容体アンタゴニストとしてのピラゾロピリミジン化合物 | |
| WO2024159067A1 (en) | Compounds and methods for yap/tead modulation and indications therefor |